ICU days are among the most expensive services a hospital provides,³ with mechanical ventilation acting as a significant incremental cost driver.⁴ Sedation strategies that reduce ventilation duration lower total ICU expenditure directly,⁵ and in both the NHS and US systems, ICU capacity remains constrained, resource-intensive, and operationally critical to overall hospital performance.⁶ Even modest reductions in ventilation time or length of stay compound across thousands of patients every year, converting incremental clinical improvements into meaningful, measurable financial impact at system level.

Internal modelling estimates that excess sedation costs the NHS approximately £71 million annually across UK ICUs, avoidable ventilation hours, prolonged stays, and downstream complications that arise when blood propofol concentration cannot be measured in real time.⁷

A single £31 ProSed® test generates approximately £62 in provider-level savings, a 2:1 return driven by fewer ventilated bed-days, earlier extubation, shorter ICU stays, and reduced complication management.⁸ Savings accrue at trust level, within the same episode of care.³ ⁵

The same mechanism operates on a materially larger cost base in the US. Somnus modelling estimates excess sedation contributes approximately $1 billion annually across US ICUs,⁷ with higher daily bed costs amplifying the return on every improvement in ventilation duration or length of stay.³ ⁴ With an estimated ~31.7 million addressable tests annually,⁹ the procedural setting adds further scale: conservative discharge protocols across ambulatory and endoscopy facilities persist because residual propofol concentrations are unknown at the point of care, constraining throughput and extending recovery times. The combined annual cost impact across ICU and procedural settings exceeds $9 billion.¹⁴

Blood propofol concentration cannot be measured in real time at the bedside, and laboratory testing remains too slow and impractical to support dynamic ICU titration.¹⁰ Clinicians therefore adjust dosing based largely on observed clinical effect, creating ongoing risk of accumulation, over-sedation, delayed extubation, and unnecessarily prolonged ICU stay. Multiple systematic reviews confirm that improved sedation practice reduces mechanical ventilation duration and ICU length of stay.⁵ ¹¹ ProSed® introduces objective near-patient measurement into this process, transforming sedation management from estimation to evidence-based control.

Over-sedation is a recognised independent risk factor for ICU delirium¹², a complication associated with prolonged ventilation, extended stays, and an annual economic burden of $38–152 billion in the US alone.¹³ Precision sedation does not need to eliminate delirium to generate value. Even modest reductions in incidence compound materially at system scale.⁵ ¹¹

conservative discharge protocols persist because residual propofol concentrations are simply unknown at the point of care.¹⁴ This uncertainty extends recovery times, limits same-day throughput, and constrains procedural capacity in high-volume environments. The estimated annual cost impact exceeds $8 billion in the United States,¹⁴ reflecting delayed discharge, lost productivity, and operational inefficiency. Objective measurement enables greater discharge confidence, improved patient flow, and higher utilisation of existing infrastructure without expanding physical capacity.